{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T07:47:45Z","timestamp":1770536865607,"version":"3.49.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> To evaluate the safety and efficacy of continuous high-dose (6 mg) intravitreal ganciclovir injections (IVG) for cytomegalovirus (CMV) retinitis (CMVR) after haploidentical hematopoietic stem cell transplantation (Haplo-HSCT), and to explore factors that may influence the treatment procedure.<\/jats:p><jats:p><jats:bold>Design:<\/jats:bold> Prospective, randomized, single-blinded, positive-controlled, interventional, comparative study.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A total of 22 patients with CMVR (32 eyes) were randomized to either high-dose group (IVG 6 mg weekly) or low-dose group (IVG 3 mg given twice weekly for 2 weeks as induction phase and weekly thereafter as maintenance phase). Patients who were recorded any positive CMV DNAemia or other active CMV diseases and needed systemic anti-CMV treatment during the study period were excluded. The vision outcome, variables of the treatment procedure, and incidence of complication and CMVR recurrence were analyzed and compared. Logistic regression was applied to determine the factors that may have an impact on the treatment process at baseline.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Compared to the low-dose group, the high-dose group resulted in a median of two less intravitreal injections (4 vs. 6 times, respectively, <jats:italic>P<\/jats:italic> = 0.016), while the rate of vision stability or improvement (81.2 vs. 87.5%), the incidence of complication (6.2 vs. 18.8%), and CMVR recurrence (12.5% vs. 6.2%) were similar (all <jats:italic>P<\/jats:italic> &amp;gt; 0.05). No drug-related toxicity was observed. Initial aqueous CMV-DNA load (OR: 6.872, 95% CI: 1.335\u201335.377, <jats:italic>P<\/jats:italic> = 0.021) and extension of lesion (OR: 0.942, 95% CI: 0.897 to .991, <jats:italic>P<\/jats:italic> = 0.020), but not dosing regimen (<jats:italic>P<\/jats:italic> = 0.162), were predictors of the treatment duration.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Continuous high-dose regimen was well tolerated and resulted in less intravitreal injections, with similar vision outcomes and safety profiles. The clinical course of CMVR after Haplo-HSCT was determined by its own nature at baseline and could not be modified by treatment protocols under consistent immune background.<\/jats:p>","DOI":"10.3389\/fmed.2021.750760","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T06:31:26Z","timestamp":1640327486000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Continuous High-Dose (6 mg) vs. Low-Dose (3 mg) Intravitreal Ganciclovir for Cytomegalovirus Retinitis After Haploidentical Hematopoietic Stem Cell Transplantation: A Randomized Controlled Study"],"prefix":"10.3389","volume":"8","author":[{"given":"Wei-Bin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e13096","DOI":"10.1111\/tid.13096","article-title":"Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia","volume":"21","author":"Lin","year":"2019","journal-title":"Transpl Infect Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/cid\/cit494","article-title":"Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review","volume":"57","author":"Ford","year":"2013","journal-title":"Clin Infect Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3760\/cma.j.issn.0412-4081.2017.10.005","article-title":"Influent factors for treating procedure of cytomegalovirus retinitis after allogeneic bone marrow hematopoietic stem cell transplantation","volume":"53","author":"Miao","year":"2017","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2020.1823422","article-title":"Efficacy and safety of aqueous interleukin-8-guided treatment in cytomegalovirus retinitis after bone marrow hematopoietic stem cell transplantation","volume":"16","author":"Zhang","year":"2020","journal-title":"Ocul Immunol Inflamm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e483","DOI":"10.1111\/aos.13787","article-title":"Aqueous cytomegalovirus DNA and interleukin-8 determination in management of cytomegalovirus retinitis","volume":"97","author":"Miao","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12886-018-0983-z","article-title":"Initial intravitreal injection of high-dose ganciclovir for cytomegalovirus retinitis in HIV-negative patients","volume":"18","author":"Qian","year":"2018","journal-title":"BMC Ophthalmol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/09273948.2019.1659978","article-title":"Prognostic factors of cytomegalovirus infection associated retinitis in HIV-negative patients: a retrospective cohort study","volume":"29","author":"Qian","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1177\/112067210501500512","article-title":"High-dose (5000-microg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela","volume":"15","author":"Arevalo","year":"2005","journal-title":"Eur J Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1089\/jop.2013.0241","article-title":"Continued decline of aqueous interleukin-8 after multiple intravitreal injections of ganciclovir for cytomegalovirus retinitis","volume":"30","author":"Wang","year":"2014","journal-title":"J Ocul Pharmacol Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/bjo.80.3.214","article-title":"High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration","volume":"80","author":"Morlet","year":"1996","journal-title":"Br J Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0928-0197(93)90012-T","article-title":"Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals","volume":"1","author":"Drew","year":"1993","journal-title":"Clin Diagn Virol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00417-014-2587-5","article-title":"Outcome of cytomegalovirus retinitis in immunocompromised patients without Human Immunodeficiency Virus treated with intravitreal ganciclovir injection","volume":"252","author":"Agarwal","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S0161-6420(98)98020-4","article-title":"High-dose (2000-microgram) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis","volume":"105","author":"Young","year":"1998","journal-title":"Ophthalmology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3109\/09273948.2014.985385","article-title":"Cytomegalovirus retinitis in a human immunodeficiency virus-negative cohort: long-term management and complications","volume":"23","author":"Jeon","year":"2015","journal-title":"Ocul Immunol Inflamm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2008","journal-title":"Clin Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1086\/346240","article-title":"Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain","volume":"187","author":"Hamprecht","year":"2003","journal-title":"J Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1086\/432012","article-title":"Cytomegalovirus (CMV) blood DNA load, CMV retinitis progression, and occurrence of resistant CMV in patients with CMV retinitis","volume":"192","author":"Jabs","year":"2005","journal-title":"J Infect Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1386-6532(01)00229-3","article-title":"High dose oral ganciclovir treatment for cytomegalovirus retinitis","volume":"24","author":"Lalezari","year":"2002","journal-title":"J Clin Virol."},{"key":"B20","first-page":"S63","article-title":"The high-dose, alternate-week intravitreal ganciclovir injections for cytomegalovirus retinitis in acquired immune deficiency syndrome patients on highly active antiretroviral therapy","volume":"88","author":"Yutthitham","year":"2005","journal-title":"J Med Assoc Thai."},{"key":"B21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12886-018-0703-8","article-title":"Repeated intraocular crystallization of ganciclovir in one eye after bilateral intravitreal injections: a case report","volume":"18","author":"Iu","year":"2018","journal-title":"BMC Ophthalmol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2147\/OPTH.S10949","article-title":"Crystallization after intravitreal ganciclovir injection","volume":"4","author":"Choopong","year":"2010","journal-title":"Clin Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1086\/381394","article-title":"Emergence of drug-resistant cytomegalovirus retinitis in the contralateral eyes of patients with AIDS treated with ganciclovir","volume":"189","author":"Imai","year":"2004","journal-title":"J Infect Dis."},{"key":"B24","first-page":"128","article-title":"Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS","volume-title":"Ophthalmology.","author":"Jabs","year":"2010"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.ophtha.2004.05.028","article-title":"Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment","volume":"111","author":"Jabs","year":"2004","journal-title":"Ophthalmology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41409-020-0790-z","article-title":"Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation","volume":"55","author":"Yan","year":"2020","journal-title":"Bone Marrow Transplant."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.750760\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T06:31:32Z","timestamp":1640327492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.750760\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":26,"alternative-id":["10.3389\/fmed.2021.750760"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.750760","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,24]]},"article-number":"750760"}}